Table 2.
Antiepileptic drugs used by mothers and major anomaly (n=117)
| Variable | Data | Major anomaly* |
|---|---|---|
| Monotherapy | 76 (83.5) | 4 (5.3) |
| VPA | 32 | |
| CBZ | 24 | |
| PB | 8 | |
| OXC | 8 | |
| PHT | 2 | |
| CLZ | 2 | |
| Polytherapy | 15 (16.5) | 3 (20.0) |
| VPA+CBZ | 2 | |
| VPA+PB | 2 | |
| VPA+LTG | 1 | |
| VPA+LTG+LEV | 1 | |
| VPA+CBZ+PHT | 1 | |
| PB+PHT | 1 | |
| PB+LTG | 1 | |
| PB+PHT+CBZ | 2 | |
| PB+PHT+CBZ+VGB | 1 | |
| PHT+PRM | 1 | |
| PHT+OXC | 1 | |
| PHT+VGB+CBZ | 1 | |
| Non-AED group | 26 | 1 (3.8) |
Values are presented as number (%) or number only.
AED, antiepileptic drug; VPA, valproic acid; CBZ, carbamazepine; PB, phenobarbital; OXC, oxcarbazepine; PHT, phenytoin; CLZ, clonazepam; LTG, lamotrigine; LEV, levetirecetam; PRM, primidone; VGB, vigabatrin.
*
p>0.05 in AED (monotherapy and polytherapy) and non-AED groups.